MCM
ORMP icon

MAI Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

MAI Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.99K Hold
2,055
– – ﹤0.01% 3335
2025
Q4 		$5.86K Hold
2,055
– – ﹤0.01% 3057
2025
Q3 		$5.43K Hold
2,055
– – ﹤0.01% 2987
2025
Q2 		$4.62K Hold
2,055
– – ﹤0.01% 3079
2025
Q1 		$4.4K Buy
+2,055
New +$4.74K ﹤0.01% 2756

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

MAI Capital Management's ORMP Position: Q1 2026 in Review

MAI Capital Management held its Oramed Pharmaceuticals (ORMP) position steady in Q1 2026 at 2,055 shares worth $6.99K. The position accounts for ﹤0.01% of the portfolio, ranked #3335.

MAI Capital Management first reported a position in ORMP in Q1 2025 and has held it in 5 quarters since. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • MAI Capital Management held 2,055 shares of Oramed Pharmaceuticals worth $6.99K as of Q1 2026.
  • MAI Capital Management left its Oramed Pharmaceuticals share count unchanged in Q1 2026.
  • Oramed Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3335 holding.
  • MAI Capital Management first reported a position in Oramed Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.